Floatz logo

MELOXIDOLOR

Migraine

Axsome Therapeutics, Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

106 Active assets in the Migraine cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
mk-1602
H. Lundbeck A/S
Phase 4BBB

View all 50 →

Same molecule, other indications

MELOXIDOLOR is also rated in:

biliary atresiaDormant
BB
Indicative ·
69 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →
prostate neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →